Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients (Q40255006)

18 September 2017

title

Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients (English)

1 reference

18 September 2017

G Ruaño

1

1 reference

18 September 2017

J W Goethe

2

1 reference

18 September 2017

C Caley

3

1 reference

18 September 2017

S Woolley

4

1 reference

18 September 2017

T R Holford

5

1 reference

18 September 2017

M Kocherla

6

1 reference

18 September 2017

A Windemuth

7

1 reference

18 September 2017

J de Leon

8

1 reference

18 September 2017

language of work or name

English

0 references

publication date

2 January 2007

1 reference

18 September 2017

1 reference

18 September 2017

volume

12

1 reference

18 September 2017

issue

5

1 reference

18 September 2017

page(s)

474-482

1 reference

Pharmacogenetics of antipsychotic-induced weight gain

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Novel antipsychotics and severe hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Clozapine-induced weight gain: prevalence and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Weight gain among schizophrenic patients treated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Weight gain from novel antipsychotic drugs: need for action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Physiogenomic analysis of weight loss induced by dietary carbohydrate restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

High density lipoprotein uptake by scavenger receptor SR-BII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

NPY and cohorts in regulating appetite, obesity and metabolic syndrome: beneficial effects of gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Highly parallel SNP genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Identifying differentially expressed genes using false discovery rate controlling procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Robust Locally Weighted Regression and Smoothing Scatterplots

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Locally Weighted Regression: An Approach to Regression Analysis by Local Fitting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Tests of linkage and/or association of the LEPR gene polymorphisms with obesity phenotypes in Caucasian nuclear families

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Polymorphisms in the PON gene cluster are associated with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Novel neuropeptide Y1 and Y5 receptor gene variants: associations with serum triglyceride and high-density lipoprotein cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Apolipoprotein E genetic variation and Alzheimer's disease. a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

APOE-epsilon4 is associated with weight loss in women with AD: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

A haplotype map of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Broad therapeutic uses of atypical antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Pharmacogenetics of psychotropic drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Pharmacogenetics for the individualization of psychiatric treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Incident Diabetes Associated With Antipsychotic Use in the United Kingdom General Practice Research Debate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

Pharmacogenetics of antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

7 January 2021

Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

7 January 2021

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

7 January 2021

Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

7 January 2021

The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

7 January 2021

A single nucleotide polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

7 January 2021

Quo vadis personalized medicine?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4001944

7 January 2021

Identifiers

DOI

10.1038/SJ.MP.4001944

1 reference

18 September 2017

1 reference